Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin and Doxycycline for COVID-19 in Iraq
NCT04591600Phase 2Completed
- Sponsor
- Al-Karkh Health Directorate
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CHILD-IVITAB and doxycycline in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Al-Karkh Health Directorate. Primary endpoints: Mortality rate at 8 weeks and Rate of progression disease at 8 weeks. Started Jul 2020; status: completed.
02
Drugs
CHILD-IVITABdoxycycline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04591600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591600.